Special Edition: What's Next—Oral GLP-1 Receptor Agonists

Special Edition: What's Next—Oral GLP-1 Receptor Agonists

In this special series on Oral GLP-1 Receptor Agonists, Dr. Neil Skolnik will discuss the first of the GLP-1 RAs to receive FDA approval, Semaglutide. This special episode is sponsored with support from Novo Nordisk.

Presented by:

Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

W. Timothy Garvey, MD., Butterworth Professor and University Professor of Medicine in the Department of Nutrition Sciences at the University of Alabama at Birmingham.

Selected references:

Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Knop, Filip K et al. The Lancet, Volume 402, Issue 10403, 705 – 719

Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. Wharton Sean et al. N Engl J Med 2025;393:1077-1087

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. Lincoff, A Michael, et al. N Engl J Med 2023;389:2221-2232

Jaksot(100)

Suosittua kategoriassa Terveys ja hyvinvointi

unicast
psykopodiaa-podcast
voi-hyvin-meditaatiot-2
tiedenaiset-podcast
vakeva-elama-viisaampi-mieli-vahvempi-keho
meditaatiot-suomeksi
puhu-muru
rss-pitaisko-erota
katilon-kahvitunti
rss-pt-paahtio
rss-kuumilla-aalloilla
rss-kyykkya-ja-kuoharia
fitnessvastaanotto
terapiassa
paritellen
junnut-pelissa
rss-uplevel-by-sonja-hannus
rss-nautinto
fitnesskulmapodcast
rss-mighty-finland-podcast